The EPO published patent EP3538160A1 covering methods and compositions for large-scale production of memory-like NK cells with therapeutic applications. The patent claims priority to multiple IPC classifications including A61K 35/17 (cell therapy), A61K 38/20 (cytokines), A61P 31/12 (antivirals), A61P 35/00 (anticancer), and A61P 37/02 (immunomodulators). The designated states cover all EU member states plus associated countries including Switzerland, Norway, and Turkey.

IP professionals and compliance officers should conduct freedom-to-operate analyses for any NK cell therapy development programs to assess potential infringement risks. R&D teams developing cell therapy products should review the specific claim scope to determine whether their manufacturing methods or compositions overlap with protected subject matter. Patent portfolio managers should update internal databases to flag this publication as prior art for competitive intelligence purposes.